Free tool
FAERS Monitor: Avsola
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761086 or its brand name (Avsola, Infliximab-Axxq). Reports on generic versions are filed under their own applications.
Reports
1,160
Serious
668
58% of reports
Hospitalization
266
Death reported
79
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use331
- product storage error143
- circumstance or information capable of leading to medication error99
- drug ineffective89
- fatigue87
- dyspnoea79
- infusion related reaction71
- diarrhoea70
- arthralgia69
- pain68
- crohn^s disease67
- nausea61
- rash61
- headache60
- pneumonia60
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 16 |
| 2021 | 84 |
| 2022 | 130 |
| 2023 | 214 |
| 2024 | 213 |
| 2025 | 139 |
| 2026 | 364 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,999 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| circumstance or information capable of leading to medication errorSignal | 99 | 53.3 | 44.1 | 5,022 |
| product storage errorSignal | 143 | 29.7 | 25.4 | 3,942 |
| infusion related reactionSignal | 71 | 19.4 | 15.5 | 1,226 |
| off label useSignal | 331 | 6.9 | 6.3 | 1,721 |
| pneumoniaSignal | 60 | 3.4 | 2.6 | 99 |
| arthralgiaSignal | 69 | 3.0 | 2.4 | 92 |
| rashSignal | 61 | 2.5 | 2.0 | 56 |
| dyspnoeaSignal | 79 | 2.5 | 2.0 | 74 |
| fatigueSignal | 87 | 2.0 | 1.7 | 46 |
| painSignal | 68 | 2.0 | 1.6 | 34 |
| diarrhoea | 70 | 2.0 | 1.6 | 33 |
| headache | 60 | 1.7 | 1.4 | 19 |
| nausea | 61 | 1.4 | 1.1 | 7 |
| drug ineffective | 89 | 1.2 | 1.0 | 4 |
| crohn^s disease | 67 | 0.0 | 0.0 | 1,197,914 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.